Abstract
The literature concerning the design of large-scale high-throughput multiplexed genotyping assays for profiling tumour somatic mutations, and studies of their validation and prospective clinical use in guiding targeted therapies, is reviewed. Reports of the design and development of genotyping approaches for the simultaneous detection of numerous oncogenic driver mutations in many known cancer genes first appeared in the literature between 2007 and 2010. Retrospective studies of the detection of somatic mutations in a representative series of human tumour specimens has provided evidence of analytical validity as well as technical accuracy and reliability. Six prospective clinical studies reported since 2011 have generated evidence supporting the clinical validity of these genotyping approaches in identifying tumour somatic mutations in cancer patients in a way that could guide their treatment options. Currently, over forty different targeted drug therapies are approved for clinical use in treating cancer that therapeutically address over sixty different cancer- associated genes and hundreds of individual oncogenic driver mutations. This expanding list of targetable cancer genes and driver mutations are now candidates for inclusion in customised genotyping designs for future clinical evaluation in guiding targeted cancer therapy.
Keywords: Cancer, mutation profiling, targeted therapies, tumour genotyping.
Current Cancer Therapy Reviews
Title:Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy
Volume: 9 Issue: 4
Author(s): Mark J. McKeage, Phillip Shepherd, Masato Yozu and Donald R. Love
Affiliation:
Keywords: Cancer, mutation profiling, targeted therapies, tumour genotyping.
Abstract: The literature concerning the design of large-scale high-throughput multiplexed genotyping assays for profiling tumour somatic mutations, and studies of their validation and prospective clinical use in guiding targeted therapies, is reviewed. Reports of the design and development of genotyping approaches for the simultaneous detection of numerous oncogenic driver mutations in many known cancer genes first appeared in the literature between 2007 and 2010. Retrospective studies of the detection of somatic mutations in a representative series of human tumour specimens has provided evidence of analytical validity as well as technical accuracy and reliability. Six prospective clinical studies reported since 2011 have generated evidence supporting the clinical validity of these genotyping approaches in identifying tumour somatic mutations in cancer patients in a way that could guide their treatment options. Currently, over forty different targeted drug therapies are approved for clinical use in treating cancer that therapeutically address over sixty different cancer- associated genes and hundreds of individual oncogenic driver mutations. This expanding list of targetable cancer genes and driver mutations are now candidates for inclusion in customised genotyping designs for future clinical evaluation in guiding targeted cancer therapy.
Export Options
About this article
Cite this article as:
McKeage J. Mark, Shepherd Phillip, Yozu Masato and R. Love Donald, Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy, Current Cancer Therapy Reviews 2013; 9 (4) . https://dx.doi.org/10.2174/157339470904140418093822
DOI https://dx.doi.org/10.2174/157339470904140418093822 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Patents Review in siRNA Delivery for Pulmonary Disorders
Recent Patents on Drug Delivery & Formulation Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews Systematic Analysis of RNAi Reports Identifies Dismal Commonality at Gene-Level and Reveals an Unprecedented Enrichment in Pooled shRNA Screens
Combinatorial Chemistry & High Throughput Screening Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Therapeutic Targeting of Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology New Functions of the Inositol Polyphosphate 5-Phosphatases in Cancer
Current Pharmaceutical Design Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Current Pharmaceutical Biotechnology Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Current Pharmaceutical Design Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer
Current Cancer Drug Targets ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry